NCT05862272 2025-08-06A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisSumitomo Pharma Switzerland GmbHPhase 3 Recruiting1,000 enrolled